-
1
-
-
78650874372
-
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
-
12748309 1:CAS:528:DC%2BD3sXkvVersbw%3D
-
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
Pryer, N.K.4
Cherrington, J.M.5
-
2
-
-
33947504730
-
Sunitinib: From rational design to clinical efficacy
-
17327610 10.1200/JCO.2006.06.3602 1:CAS:528:DC%2BD2sXjvVKmtLY%3D
-
Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896
-
(2007)
J Clin Oncol
, vol.25
, pp. 884-896
-
-
Chow, L.Q.1
Eckhardt, S.G.2
-
3
-
-
33749544080
-
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
-
16849418 10.1210/jc.2005-2845 1:CAS:528:DC%2BD28XhtFSjtbrN
-
Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 4070-4076
-
-
Kim, D.W.1
Jo, Y.S.2
Jung, H.S.3
Chung, H.K.4
Song, J.H.5
Park, K.C.6
Park, S.H.7
Hwang, J.H.8
Rha, S.Y.9
Kweon, G.R.10
Lee, S.J.11
Jo, K.W.12
Shong, M.13
-
4
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
12538485 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D
-
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
-
(2003)
Clin Cancer Res
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
Schreck, R.E.7
Abrams, T.J.8
Ngai, T.J.9
Lee, L.B.10
Murray, L.J.11
Carver, J.12
Chan, E.13
Moss, K.G.14
Haznedar, J.O.15
Sukbuntherng, J.16
Blake, R.A.17
Sun, L.18
Tang, C.19
Miller, T.20
Shirazian, S.21
McMahon, G.22
Cherrington, J.M.23
more..
-
5
-
-
9144274970
-
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
-
14713109 10.1023/B:CLIN.0000006873.65590.68 1:CAS:528: DC%2BD3sXpsV2ktbk%3D
-
Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766
-
(2003)
Clin Exp Metastasis
, vol.20
, pp. 757-766
-
-
Murray, L.J.1
Abrams, T.J.2
Long, K.R.3
Ngai, T.J.4
Olson, L.M.5
Hong, W.6
Keast, P.K.7
Brassard, J.A.8
O'Farrell, A.M.9
Cherrington, J.M.10
Pryer, N.K.11
-
6
-
-
0038204144
-
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
12531805 10.1182/blood-2002-07-2307
-
O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605
-
(2003)
Blood
, vol.101
, pp. 3597-3605
-
-
O'Farrell, A.M.1
Abrams, T.J.2
Yuen, H.A.3
Ngai, T.J.4
Louie, S.G.5
Yee, K.W.6
Wong, L.M.7
Hong, W.8
Lee, L.B.9
Town, A.10
Smolich, B.D.11
Manning, W.C.12
Murray, L.J.13
Heinrich, M.C.14
Cherrington, J.M.15
-
8
-
-
36249021985
-
Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling
-
17691110 10.1002/ijc.22999 1:CAS:528:DC%2BD2sXhtl2qsLzF
-
Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C (2007) Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121:2606-2614
-
(2007)
Int J Cancer
, vol.121
, pp. 2606-2614
-
-
Hasumi, Y.1
Klosowska-Wardega, A.2
Furuhashi, M.3
Ostman, A.4
Heldin, C.H.5
Hellberg, C.6
-
9
-
-
0031045574
-
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer
-
9052396 10.1038/bjc.1997.83 1:CAS:528:DyaK2sXhslWisLc%3D
-
Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL (1997) Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75:477-481
-
(1997)
Br J Cancer
, vol.75
, pp. 477-481
-
-
Koukourakis, M.I.1
Giatromanolaki, A.2
O'Byrne, K.J.3
Comley, M.4
Whitehouse, R.M.5
Talbot, D.C.6
Gatter, K.C.7
Harris, A.L.8
-
10
-
-
23844545810
-
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas
-
16103075 10.1158/0008-5472.CAN-04-4171 1:CAS:528:DC%2BD2MXns1Wrur0%3D
-
Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S, Sata S, Nakagawa K, Yoshino I, Maehara Y, Sueishi K (2005) Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 65:7241-7248
-
(2005)
Cancer Res
, vol.65
, pp. 7241-7248
-
-
Shikada, Y.1
Yonemitsu, Y.2
Koga, T.3
Onimaru, M.4
Nakano, T.5
Okano, S.6
Sata, S.7
Nakagawa, K.8
Yoshino, I.9
Maehara, Y.10
Sueishi, K.11
-
11
-
-
0035863288
-
Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer
-
11208836 1:CAS:528:DC%2BD3MXhtVekt7Y%3D
-
Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, Lee YC (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432-441
-
(2001)
J Clin Oncol
, vol.19
, pp. 432-441
-
-
Yuan, A.1
Yu, C.J.2
Kuo, S.H.3
Chen, W.J.4
Lin, F.Y.5
Luh, K.T.6
Yang, P.C.7
Lee, Y.C.8
-
13
-
-
70350655546
-
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
-
19826424 10.1038/sj.bjc.6605346 1:CAS:528:DC%2BD1MXhtlWmu7fF
-
Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 101:1543-1548
-
(2009)
Br J Cancer
, vol.101
, pp. 1543-1548
-
-
Novello, S.1
Scagliotti, G.V.2
Rosell, R.3
Socinski, M.A.4
Brahmer, J.5
Atkins, J.6
Pallares, C.7
Burgess, R.8
Tye, L.9
Selaru, P.10
Wang, E.11
Chao, R.12
Govindan, R.13
-
14
-
-
79851482955
-
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
-
21306237 10.1056/NEJMoa1003825 1:CAS:528:DC%2BC3MXhvVyisrY%3D
-
Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
-
(2011)
N Engl J Med
, vol.364
, pp. 501-513
-
-
Raymond, E.1
Dahan, L.2
Raoul, J.-L.3
Bang, Y.-J.4
Borbath, I.5
Lombard-Bohas, C.6
Valle, J.7
Metrakos, P.8
Smith, D.9
Vinik, A.10
Chen, J.S.11
Hörsch, D.12
Hammel, P.13
Wiedenmann, B.14
Van Cutsem, E.15
Patyna, S.16
Lu, D.R.17
Blanckmeister, C.18
Chao, R.19
Ruszniewski, P.20
more..
-
15
-
-
72549097409
-
A phase i study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors
-
abstract 2911
-
Rosen LS, Bello CL, Mulay M, Dinolfo M, Baum C (2006) A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors. In: Proceedings of the 97th American Association for Cancer Research 47; abstract 2911
-
(2006)
Proceedings of the 97th American Association for Cancer Research 47
-
-
Rosen, L.S.1
Bello, C.L.2
Mulay, M.3
Dinolfo, M.4
Baum, C.5
-
16
-
-
39149120621
-
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
-
18235126 10.1200/JCO.2007.13.9303 1:CAS:528:DC%2BD1cXis1alsbs%3D
-
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656
-
(2008)
J Clin Oncol
, vol.26
, pp. 650-656
-
-
Socinski, M.A.1
Novello, S.2
Brahmer, J.R.3
Rosell, R.4
Sanchez, J.M.5
Belani, C.P.6
Govindan, R.7
Atkins, J.N.8
Gillenwater, H.H.9
Pallares, C.10
Tye, L.11
Selaru, P.12
Chao, R.C.13
Scagliotti, G.V.14
-
17
-
-
70249084594
-
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
-
19652072 10.1200/JCO.2008.20.5476 1:CAS:528:DC%2BD1MXhtF2jtL3J
-
Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ (2009) Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4068-4075
-
(2009)
J Clin Oncol
, vol.27
, pp. 4068-4075
-
-
Escudier, B.1
Roigas, J.2
Gillessen, S.3
Harmenberg, U.4
Srinivas, S.5
Mulder, S.F.6
Fountzilas, G.7
Peschel, C.8
Flodgren, P.9
Maneval, E.C.10
Chen, I.11
Vogelzang, N.J.12
-
18
-
-
67249147869
-
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
-
19282169 10.1016/j.ejca.2009.02.011 1:CAS:528:DC%2BD1MXotFCjs7Y%3D
-
George S, Blay JY, Casali PG, Le CA, Stephenson P, DePrimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959-1968
-
(2009)
Eur J Cancer
, vol.45
, pp. 1959-1968
-
-
George, S.1
Blay, J.Y.2
Casali, P.G.3
Le, C.A.4
Stephenson, P.5
Deprimo, S.E.6
Harmon, C.S.7
Law, C.N.8
Morgan, J.A.9
Ray-Coquard, I.10
Tassell, V.11
Cohen, D.P.12
Demetri, G.D.13
-
19
-
-
35148857486
-
Sunitinib efficacy against advanced renal cell carcinoma
-
17868732 10.1016/j.juro.2007.07.030 1:CAS:528:DC%2BD2sXht12rtrvN
-
Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G (2007) Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178:1883-1887
-
(2007)
J Urol
, vol.178
, pp. 1883-1887
-
-
Motzer, R.J.1
Michaelson, M.D.2
Rosenberg, J.3
Bukowski, R.M.4
Curti, B.D.5
George, D.J.6
Hudes, G.R.7
Redman, B.G.8
Margolin, K.A.9
Wilding, G.10
-
20
-
-
79955728914
-
Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial
-
abstract LBA308
-
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Martell B, Hariharan S, Figlin RA (2011) Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT Trial. J Clin Oncol 29(Suppl 7); abstract LBA308
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 7
-
-
Motzer, R.J.1
Hutson, T.E.2
Olsen, M.R.3
Hudes, G.R.4
Burke, J.M.5
Edenfield, W.J.6
Wilding, G.7
Martell, B.8
Hariharan, S.9
Figlin, R.A.10
-
21
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
-
18506025 10.1200/JCO.2007.15.0375 1:CAS:528:DC%2BD1cXpvVWmtLg%3D
-
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
Von Pawel, J.3
Biesma, B.4
Vansteenkiste, J.5
Manegold, C.6
Serwatowski, P.7
Gatzemeier, U.8
Digumarti, R.9
Zukin, M.10
Lee, J.S.11
Mellemgaard, A.12
Park, K.13
Patil, S.14
Rolski, J.15
Goksel, T.16
De Marinis, F.17
Simms, L.18
Sugarman, K.P.19
Gandara, D.20
more..
-
22
-
-
0041629528
-
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
-
12860938 10.1200/JCO.2003.11.136 1:CAS:528:DC%2BD2cXptlCktL4%3D
-
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644
-
(2003)
J Clin Oncol
, vol.21
, pp. 2636-2644
-
-
Vogelzang, N.J.1
Rusthoven, J.J.2
Symanowski, J.3
Denham, C.4
Kaukel, E.5
Ruffie, P.6
Gatzemeier, U.7
Boyer, M.8
Emri, S.9
Manegold, C.10
Niyikiza, C.11
Paoletti, P.12
-
23
-
-
84874105407
-
A phase i dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
-
Oct 12 (e-pub ahead of print)
-
Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR (2011) A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol Oct 12 (e-pub ahead of print)
-
(2011)
Cancer Chemother Pharmacol
-
-
Chow, L.Q.1
Blais, N.2
Jonker, D.J.3
Laurie, S.A.4
Diab, S.G.5
Canil, C.6
McWilliam, M.7
Thall, A.8
Ruiz-Garcia, A.9
Zhang, K.10
Tye, L.11
Chao, R.C.12
Camidge, D.R.13
-
24
-
-
77955700137
-
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase i dose-escalation study
-
20188433 10.1016/j.lungcan.2010.01.016
-
Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr H-G, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E (2010) Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 70:180-187
-
(2010)
Lung Cancer
, vol.70
, pp. 180-187
-
-
Reck, M.1
Frickhofen, N.2
Cedres, S.3
Gatzemeier, U.4
Heigener, D.5
Fuhr, H.-G.6
Thall, A.7
Lanzalone, S.8
Stephenson, P.9
Ruiz-Garcia, A.10
Chao, R.11
Felip, E.12
-
25
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
26
-
-
1342267614
-
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
-
14760119 10.1093/annonc/mdh059 1:STN:280:DC%2BD2c%2FlvVamtg%3D%3D
-
Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260
-
(2004)
Ann Oncol
, vol.15
, pp. 257-260
-
-
Byrne, M.J.1
Nowak, A.K.2
-
27
-
-
77951230703
-
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
-
20423465 10.1186/1756-9966-29-38
-
Zhang GZ, Jiao SC, Meng ZT (2010) Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 29:38
-
(2010)
J Exp Clin Cancer Res
, vol.29
, pp. 38
-
-
Zhang, G.Z.1
Jiao, S.C.2
Meng, Z.T.3
-
28
-
-
42949148257
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
18347007 10.1200/JCO.2007.14.5375 1:CAS:528:DC%2BD1cXmsFemsb8%3D
-
Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816
-
(2008)
J Clin Oncol
, vol.26
, pp. 1810-1816
-
-
Burstein, H.J.1
Elias, A.D.2
Rugo, H.S.3
Cobleigh, M.A.4
Wolff, A.C.5
Eisenberg, P.D.6
Lehman, M.7
Adams, B.J.8
Bello, C.L.9
Deprimo, S.E.10
Baum, C.M.11
Miller, K.D.12
-
29
-
-
79955728914
-
Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial
-
abstract LBA308
-
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Martell B, Hariharan S, Figlin RA (2011) Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT Trial. J Clin Oncol 29(suppl 7); abstract LBA308
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 7
-
-
Motzer, R.J.1
Hutson, T.E.2
Olsen, M.R.3
Hudes, G.R.4
Burke, J.M.5
Edenfield, W.J.6
Wilding, G.7
Martell, B.8
Hariharan, S.9
Figlin, R.A.10
-
30
-
-
80054897151
-
Brief Report: A phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group
-
22005473 10.1097/JTO.0b013e3182333df5
-
Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, Foo AH, Seely J, Goffin JR, Laberge F, Murray N, Rao S, Nicholas G, Laskin J, Reiman T, Sauciuc D, Seymour L (2011) Brief Report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J Thorac Oncol 6:1950-1954
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1950-1954
-
-
Laurie, S.A.1
Gupta, A.2
Chu, Q.3
Lee, C.W.4
Morzycki, W.5
Feld, R.6
Foo, A.H.7
Seely, J.8
Goffin, J.R.9
Laberge, F.10
Murray, N.11
Rao, S.12
Nicholas, G.13
Laskin, J.14
Reiman, T.15
Sauciuc, D.16
Seymour, L.17
-
31
-
-
77951639655
-
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
-
20212250 10.1200/JCO.2009.26.1321 1:CAS:528:DC%2BC3cXmsFyitL0%3D
-
Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842
-
(2010)
J Clin Oncol
, vol.28
, pp. 1835-1842
-
-
Scagliotti, G.1
Novello, S.2
Von Pawel, J.3
Reck, M.4
Pereira, J.R.5
Thomas, M.6
Abrão Miziara, J.E.7
Balint, B.8
De Marinis, F.9
Keller, A.10
Arén, O.11
Csollak, M.12
Albert, I.13
Barrios, C.H.14
Grossi, F.15
Krzakowski, M.16
Cupit, L.17
Cihon, F.18
Dimatteo, S.19
Hanna, N.20
more..
-
32
-
-
79953029071
-
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
-
21336183 10.1097/JTO.0b013e31820cf053
-
Camidge DR, Kono SA, Lu X, Okuyama S, Barón AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W, Doebele RC (2011) Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6:774-780
-
(2011)
J Thorac Oncol
, vol.6
, pp. 774-780
-
-
Camidge, D.R.1
Kono, S.A.2
Lu, X.3
Okuyama, S.4
Barón, A.E.5
Oton, A.B.6
Davies, A.M.7
Varella-Garcia, M.8
Franklin, W.9
Doebele, R.C.10
|